The ΔNp63α phosphoprotein binds the p21 and 14-3-3σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations

Molecular and Cellular Biology

Volumn 23, Issue 7, 2003, Pages 2264-2276

  Westfall, Matthew D ^a   Mays, Deborah J ^a   Sniezek, Joseph C ^a,b   Pietenpol, Jennifer A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN; PROTEIN P21; PROTEIN P53; PROTEIN P63;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; EPIDERMIS; EPITHELIUM; GENE MUTATION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUTH MUCOSA; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RNA SPLICING; STEM CELL; TRANSCRIPTION REGULATION; UROGENITAL SYSTEM;

ABNORMALITIES, MULTIPLE; ALTERNATIVE SPLICING; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; ECTODERMAL DYSPLASIA; EXONUCLEASES; GENES, TUMOR SUPPRESSOR; HUMANS; KERATINOCYTES; KIDNEY; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; POINT MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN ISOFORMS; REPRESSOR PROTEINS; SYNDROME; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0037377761     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.7.2264-2276.2003     Document Type: Article

References (61)

1. Amann, J. M., J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N. Lenny, J. R. Downing, S. Meyers, and S. W. Hiebert. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21:6470-6483.
2. Augustin, M., C. Bamberger, D. Paul, and H. Schmale. 1998. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm. Genome 9:899-902.
3. Barrandon, Y., and H. Green. 1985. Cell size as a determinant of the clone-forming ability of human keratinocytes. Proc. Natl. Acad Sci. USA 82:5390-5394.
4. Barrandon, Y., and H. Green. 1987. Three clonal types of keratinocyte with different capacities for multiplication. Proc. Natl. Acad. Sci. USA 84:2302-2306.
5. Celli, J., P. Duijf, B. Hamel, M. Bamshad, B. Kramer, A. Smits, R. Newhury-Ecob, R. Hennekam, G. Van Buggenhout, A. van Haeringen, C. Woods, A. van Essen, R. de Waal, G. Vriend, D. Haber, A. Yang, F. McKeon, H. Brunner, and H. van Bokhoven. 1999. Heterozygous germline muations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99:143-153.
6. Chan, T. A., H. Hermeking, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1999. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620.
7. Chen, X. 1999. The p53 family: same response, different signals? Mol. Med. Today 5:387-392.
8. Chi, S. W., A. Ayed, and C. H. Arrowsmith. 1999. Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 18:4438-4445.
9. Choi, H. R., J. G. Batsakis, F. Zhan, E. Sturgis, M. A. Luna, and A. K. El-Naggar. 2002. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum. Pathol. 33:158-164.
10. Davison, T. S., C. Vagner, M. Kaghad, A. Ayed, D. Caput, and C. H. Arrowsmith. 1999. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J. Biol. Chem. 274:18709-18714.
11. Dellambra, E., O. Golisano, S. Siviero Bondanza, E. P. Lacal, M. Molinari, S. D'Atri, and M. DeLuca. 2000. Downregulation of 14-3-3σ prevents clonal evolution and leads to immortalization of primary human keratinocytes. J. Cell Biol. 149:1117-1129.
12. Dellavalle, R. P., T. B. Egbert, A. Marchbank, L. J. Su, L. A. Lee, and P. Walsh. 2001. CUSP/p63 expression in rat and human tissues. J. Dermatol. Sci. 27:82-87.
13. Di Como, C. J., M. J. Urist, I. Babayan, M. Drobnjak, C. V. Hedvat, J. Teruya-Feldstein, K. Pohar, A. Hoos, and C. Cordon-Cardo. 2002. p63 expression profiles in human normal and tumor tissues. Clin. Cancer. Res. 8:494-501.
14. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
15. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
16. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:2910-2919.
17. Flatt, P. M., J. O. Price, A. Shaw, and J. A. Pietenpol. 1998. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth Differ. 9:535-543.
18. 2 checkpoint is retinoblastoma protein dependent. Mol. Cell. Biol. 20:4210-4223.
19. Flores, E. R., K. Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, and T. Jacks. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-564.
20. Fuchs, E., and C. Byrne. 1994. The epidermis: rising to the surface. Curr. Opin. Genet. Dev. 4:725-736.
21. Gaiddon, C., M. Lokshin, J. Ahn, T. Zhang, and C. Prives. 2001. A subset of tumor-derived mutant forms of p53 downregulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21:1874-1887.
22. Gu, Y., C. W. Turck, and D. O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710.
23. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
24. 2/M progression. Mol. Cell 1:3-11.
25. Hibi, K., B. Trink, M. Patturajan, W. Westra, O. Caballero, D. Hill, E. Ratovitski, J. Jen, and D. Sidransky. 2000. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 97:5462-5467.
26. Irwin, M., M. C. Marin, A. C. Phillips, R. S. Seelan, D. I. Smith, L. Wanguo, E. R. Flores, K. Y. Tsai, T. Jacks, K. H. Vousden, and W. G. Kaelin. 2002. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407:642-645.
27. Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. Biscan, A. Valent, A. Minty, P. Chalon, J. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:808-819.
28. Kojima, T., Y. Ikawa, and I. Katoh. 2001. Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors. Biochem. Biophys. Res. Commun. 281:1170-1175.
29. WAF1/Cip1 gene by the p53 tumor suppressor protein. J. Biol. Chem. 276:29116-29125.
30. Lee, H., and D. Kimelman. 2002. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev. Cell 2:607-616.
31. Leigh, I., E. Lane, and F. Watt. 1994. The keratinocyte handbook. Cambridge University Press, Cambridge, United Kingdom.
32. Liefer, K., M. Koster, X. Wang, A. Yang, F. McKeon, and D. Roop. 2000. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res. 60:4016-4020.
33. Liu, M., and J. C. Pelling. 1995. UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression. Oncogene 10:1955-1960.
34. Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935-944.
35. McGrath, J. A., P. H. G. Duijf, V. Doetsch, A. D. Irvine, R. de Waal, K. R. J. Vanmolkot, V. Wessagowit, A. Kelly, D. J. Atherton, W. A. D. Griffiths, S. J. Orlow, A. van Haeringen, M. G. E. M. Ausems, A. Yang, F. McKeon, M. A. Bamshad, H. G. Brunner, B. C. J. Hamel, and H. van Bokhoven. 2001. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum. Mol. Genet. 10:221-229.
36. Mills, A. A., B. H. Zheng, X. J. Wang, H. Vogel, D. R. Roop, and A. Bradley. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713.
37. Missero, C., E. Calautti, R. Eckner, J. Chin, L. H. Tsai, D. M. Livingston, and G. P. Dotto. 1995. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA 92:5451-5455.
38. Nylander, K., P. J. Coates, and P. A. Hall. 2000. Characterization of the expression pattern of p63α and ΔNp63α in benign and malignant oral epithelial lesions. Int. J. Cancer 87:368-372.
39. Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839-843.
40. Pagliuca, A., G. Pasquale, and L. Lania. 2000. Differential role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes. J. Cell Biochem. 76:360-367.
41. Parsa, R., A. Yang, F. McKeon, and H. Green. 1999. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J. Investig. Dermatol. 113:1099-1105.
42. Pellegrini, G., E. Dellambra, O. Golisano, E. Martinelli, I. Fantozzi, S. Bondanza, D. Ponzin, F. McKeon, and M. De Luca. 2001. p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. USA 98:3156-3161.
43. Cip1/WAF1 in keratinocyte differentiation. J. Biol. Chem. 272:1308-1314.
44. Ratovitski, E. A., M. Patturajan, K. Hibi, B. Trink, K. Yamaguchi, and D. Sidransky. 2001. p53 associates with and targets ΔNp63 into a protein degradation pathway. Proc. Natl. Acad. Sci. USA 98:1817-1822.
45. WAF1/CIP1 expression in keratinocyte differentiation. Proc. Natl. Acad. Sci. USA 98:9575-9580.
46. Schultz, J., C. P. Ponting, K. Hofmann, and P. Bork. 1997. SAM as a protein interaction domain involved in developmental regulation. Protein Sci. 6:249-253.
47. Shibata, H., Z. Nawaz, S. Y. Tsai, B. W. O'Malley, and M. J. Tsai. 1997. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). Mol. Endocrinol 11:714-724.
48. WAF-1/CIP1 during differentiation. Oncogene 9:389-396.
49. Stewart, Z. A., and J. A. Pietenpol. 2001. p53 signaling and cell cycle checkpoints. Chem. Res. Toxicol. 14:243-263.
50. Strano, S., G. Fontemaggi, A. Costanzo, M. G. Rizzo, O. Monti, A. Baccarini, G. Del Sal, M. Levrero, A. Sacchi, M. Oren, and G. Blandino. 2002. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277:18817-18826.
51. Sun, T. T., and H. Green. 1976. Differentiation of the epidermal keratinocyte in cell culture: formation of the cornified envelope. Cell 9:511-521.
52. Szak, S. T., D. Mays, and J. A. Pietenpol. 2001. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21:3375-3386.
53. Thanos, C. D., and J. U. Bowie. 1999. p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci. 8:1708-1710.
54. Trink, B., K. Okami, L. Wu, V. Sriuranpong, J. Jen, and D. Sidransky. 1998. A new human p53 homologue. Nat. Med. 4:747-748.
55. Weinberg, W. C., C. G. Azzoli, K. Chapman, A. J. Levine, and S. H. Yuspa. 1995. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 10:2271-2279.
56. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
57. Yang, A., M. Kaghad, Y. Wang, E. Gillet, M. Fleming, V. Dotsch, N. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305-316.
58. Yang, A., R. Schweitzer, D. Sun, M. Kaghad, N. Walker, R. Bronson, C. Tabin, A. Sharpe, D. Caput, C. Crum, and F. McKeon. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718.
59. Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, A. Sharpe, F. McKeon, and D. Caput. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
60. Zhang, W., L. Grasso, C. D. McClain, A. M. Gambel, Y. Cha, S. Travali, A. B. Deisseroth, and W. E. Mercer. 1995. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 55:668-674.
61. Ziegler, A., A. S. Jonason, D. J. Leffell, J. A. Simon, H. W. Sharma, J. Kimmelman, L. Remington, T. Jacks, and D. E. Brash. 1994. Sunburn and p53 in the onset of skin cancer. Nature 372:773-776.